{"id":"W4399517501","doi":"10.1136/ijgc-2024-005588","title":"A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)","year":2024,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Oncology; Cervical cancer; Internal medicine; Cancer; Urology; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006486006,0.0004097746,0.001959152,0.0004046343,0.0001040797,0.00009172546,0.000420288,0.0002541192,0.002145709],"category_scores_gemma":[0.0007085145,0.0002351387,0.001206669,0.0004548866,0.0002730419,0.0002226034,0.0001247745,0.0005374535,0.000007044305],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001653632,"about_ca_system_score_gemma":0.001609463,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000261544,"about_ca_topic_score_gemma":0.0001719982,"domain_scores_codex":[0.9961172,0.0001512425,0.001627907,0.0004696961,0.001182556,0.0004513701],"domain_scores_gemma":[0.9955032,0.001742849,0.0007079604,0.0001405479,0.001546627,0.0003587785],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8547136,0.003301468,0.00008885682,0.0001604821,0.004210532,0.0004565642,0.0006139561,0.00005497366,0.0003239845,0.0004182285,0.001218425,0.1344389],"study_design_scores_gemma":[0.9396681,0.02999631,0.0006089646,0.001380831,0.002168777,0.0002189746,0.0001274525,0.002827011,0.005470115,0.001035113,0.01613511,0.0003631895],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9721704,0.009095727,0.001039761,0.005703059,0.006739017,0.003678724,0.0005440949,0.00004635908,0.0009828757],"genre_scores_gemma":[0.9910004,0.003296025,0.0007186849,0.0004285722,0.002333467,0.001230327,0.00006176172,0.00003353236,0.0008972042],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1340758,"threshold_uncertainty_score":0.9987665,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07864419944511089,"score_gpt":0.4285225515594585,"score_spread":0.3498783521143476,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}